ABOUT US
Our Mission
Our mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.
While seeking to move Ibogaine through Clinical Trials in Canada, we are building a network of holistic recovery clinics and a state of the art treatment program centred around new treatment modalities.
BOARD OF DIRECTORS
Nick Karos
Chair of the Board
Nick Karos - Chair of the Board
Nick Karos is the CEO and Board Chair of Universal Ibogaine. Over his extensive career, he has held senior roles at a leading U.S. Investment bank, gaining decades of experience in finance, capital markets, and corporate leadership. During his time as the Head of Nasdaq Trading and Agency Services at Piper Jaffray, Nick worked closely with leading medical and biotech companies, helping many of them go public through IPOs. He later served as CEO of Private Trading Group, a firm with strong relationships across major financial institutions and the biomedical sector, where he expanded the firm's global reach and built strategic partnerships with companies worldwide.
Nick also served as a Board Director of the national Security Traders Association (STA), representing trading professionals across the U.S. and Canada and gaining valuable insight into regulatory developments and industry trends.
Nick is deeply committed to transforming addiction treatment, bringing the same discipline he applied in finance to building innovative, compassionate solutions for recovery. He has also served on the Board of Directors for his church, where he combined governance experience with his passion for philanthropy and community service.
Nick's career reflects both deep financial experience and a passion for creating positive change. With a background spanning financial markets, corporate leadership, and community governance, he leads Universal Ibogaine with integrity and a clear vision for advancing addiction treatment.
James Duncan
Director
James Duncan - Director
Mr. Duncan is Director of Sales & Trading with Toronto based Independent Trading Group (ITG), and has been an active trader in the Canadian markets for 40 years, covering accounts from the EU, US and Canada, both retail and institutional. James has always been active in the trading community, serving Security Traders Associations ("STA") across the country and was Chairman of the STA in the United States in 2004 as well as serving as chair of the CSTA in Canada. He founded the Bay Street Children's foundation in 2000 and currently serves as its Chairman. James and his team have raised multiple millions for children's charities in Toronto.
Nia Killebrew
Director
Nia Killebrew - Director
Nia Killebrew is a medical malpractice attorney based in Las Vegas with decades of experience navigating complex healthcare litigation. She earned her undergraduate degree from the University of Manitoba in 1986 and obtained her Juris Doctorate from Southwestern University School of Law in 1989. Licensed in both California and Nevada, she is currently a partner at The Richard Harris Law Firm.
Her extensive background in healthcare law provides her with a nuanced understanding of the systemic challenges faced by medical providers, enabling her to offer valuable guidance on regulatory compliance and patient safety. Nia has successfully represented clients in numerous high-profile cases, securing multi-million dollar recoveries in medical malpractice and general civil litigation. Notably, she served as lead counsel in the significant Hepatitis outbreak litigation, culminating in several multi-million dollar jury verdicts. Nia also served as the partner in charge of overseeing the firm's Route 91 complex tort litigation resulting in a global 800 million dollar landmark settlement.
Known for her commitment to patient advocacy and ethical legal practice, Nia brings a trusted, client-centered perspective to healthcare issues. Her experience positions her well to contribute strategic insight and governance oversight in healthcare-related organizations and corporations.
Tony Wagner
Director
Tony Wagner - Director
Mr. Wagner has over 35 years of experience in basic science, clinical research, and strategic scientific alliance development. Tony received a PhD in Physiology and Biophysics from Keck School of Medicine of the University of Southern California and completed a Post-Doctoral Fellowship at Warren Alpert Medical School of Brown University. He then spent 22 years in Clinical Development at Amgen working across all Hematology/Oncology products, including developing external collaborations with premier research organizations and the National Cancer Institute.
Tony moved to Jazz Pharmaceuticals where he was the Global Clinical Lead for a leukemia therapy and worked on solid tumor products. Tony is currently an Executive Medical Director at Summit Therapeutics where he is developing collaborations with Global Cancer Cooperative Groups that are intended to support regulatory approval of immunotherapy and targeted cancer therapy products.
Dr Dean Koumontzis
Board Advisor
Dr. Dean Koumontzis - Board Advisor
Dr. Koumontzis is an expert in orthopedic surgery and sports medicine with an emphasis on treating disorders of the elbow, shoulder and knee. He also serves as Director of the Bone Health Clinic at TOCA at Banner Health. He has been an invited faculty member of prestigious institutions across the country and has also served on many orthopedic and sports medicine committees throughout his career. His abstracts, manuscripts, and articles have been published in numerous scientific journals, magazines and textbooks, and his lectures and presentations have gained national and international recognition. Dr. Koumontzis has also served as team physician and orthopedic consultant at Arizona State University and has several years of non-profit Board experience, serving in a variety of positions. He is based in Scottsdale, Arizona, and is CEO of Bone Health Solutions, which creates educational web based platforms and clinical system management solutions.
Eric Hrimech
Director
Eric Hrimech - Director
Mr. Hrimech has over 30 years in the medical and life science industry, and over 25 years of leadership roles including Siemens Healthcare and Abbot Labs, where he has global executive experience. He is a Board member of Trigone medical, and is currently Chief Commercial Officer for Buhlmann Laboratories AG.
MANAGEMENT TEAM
Nick Karos
Chief Executive Officer
Nick Karos, Chief Executive Officer / Director of Capital Markets
Nick Karos is the CEO and Board Chair of Universal Ibogaine. Over his extensive career, he has held senior roles at a leading U.S. Investment bank, gaining decades of experience in finance, capital markets, and corporate leadership. During his time as the Head of Nasdaq Trading and Agency Services at Piper Jaffray, Nick worked closely with leading medical and biotech companies, helping many of them go public through IPOs. He later served as CEO of Private Trading Group, a firm with strong relationships across major financial institutions and the biomedical sector, where he expanded the firm's global reach and built strategic partnerships with companies worldwide.
Nick also served as a Board Director of the national Security Traders Association (STA), representing trading professionals across the U.S. and Canada and gaining valuable insight into regulatory developments and industry trends.
Nick is deeply committed to transforming addiction treatment, bringing the same discipline he applied in finance to building innovative, compassionate solutions for recovery. He has also served on the Board of Directors for his church, where he combined governance experience with his passion for philanthropy and community service.
Nick's career reflects both deep financial experience and a passion for creating positive change. With a background spanning financial markets, corporate leadership, and community governance, he leads Universal Ibogaine with integrity and a clear vision for advancing addiction treatment.
Stay Up To Date
ABOUT US
Our Path Forward
Universal Ibogaine intends to acquire a network of addiction treatment clinics, licensing our treatment protocols to best in class treatment providers around the globe.
01
Clinic Acquisition
Acquire & Optimize program delivery
02
R&D
Clinical Trials in Canada
03
Support
Education, Awareness, and Ongoing Care
04
Growth
Acquire, Operate & License Care Facilities
Now is your chance to be part of the solution
The safety protocol developed at our research partner clinic has successfully aided over 3700 people with zero ibogaine fatalities. This is a revolution.
